Abstracts Presented at the 2024 WIN Symposium in Partnership with Burjeel Holdings

Posted: Thursday, May 23, 2024

The WIN Symposium 2024, a landmark event in precision oncology, took place in Abu Dhabi, United Arab Emirates (UAE), on the 1st and 2nd of March 2024; marking a significant collaboration between the Worldwide
Innovative Network (WIN) Consortium and Burjeel Holdings. This annual global congress of the WIN Consortium brought together physicians, researchers, and scientists from 30 countries to explore the latest advancements in precision oncology, with the ultimate goal of improving cancer patient care and outcomes worldwide.
The call for abstracts attracted 51 submissions with 42 accepted as posters and 3 as oral presentations. This publication features 34 of the accepted abstracts.

The WIN Consortium, a non-profit association headquartered in France, unites 31 world-class academic medical centers, healthcare industries, research organizations, and patient advocacy groups from 18 countries, aligned to launch cancer trials using omic platforms to bolster precision oncology across the world. BMC — Burjeel Medical City, the flagship facility of Burjeel Holdings, is the first member from the UAE and Gulf Cooperation Council countries to join the WIN Consortium.
Abu Dhabi was selected as the city to host this year’s congress, marking its inaugural occurrence outside of its traditional place in Europe.

The congress featured a meticulously curated program, including interactive elements that illustrate the principles and best practices of precision cancer treatment including dedicated sessions for precision genomics, precision immunotherapy,
precision radiotherapy, precision communityomics, a molecular tumor board, and a precision diagnostics panel. Under the theme ‘Precision and Molecular Oncology: Caring for Patients and Future Generations,’ the congress kicked off with a grand
opening featuring 2018 Nobel Laureate, Prof. James Allison, Regental Professor and Chair of the Department of Immunology at the MD Anderson Cancer Center (USA), whose groundbreaking work has revolutionized cancer
immunotherapy. He was then joined by leading key opinion leaders and innovators from prestigious institutions such as MD Anderson Cancer Center, Brown University, Weill Cornell Medicine, Mount Sinai, Mayo Clinic, Cleveland Clinic, UC San
Diego, University of Calgary, Virginia Commonwealth University, and Sarah Cannon Research Institute and renowned leaders of major precision diagnostic companies such as Guardant Health, Tempus AI, and OncoHelix. Additionally, the
platform empowered local physicians and scientists to showcase the UAE's vision and plans for genomic medicine and precision oncology.

Conference Co-Chairs were Drs Wafik El-Deiry (Chair of WIN Consortium; American Cancer Society Research Professor; Director of Legorreta Cancer Center; Associate Dean of Oncologic Sciences, Warren Alpert Medical School, Brown University, RI, USA), Razelle Kurzrock (Chief Medical Officer & Equal Opportunities and Diversity Officer of WIN
Consortium; Professor of Medicine, Associate Director of Clinical Research, Chair of Precision Oncology, MCW Cancer Center and Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine; Founding Director of
Michels Rare Cancers Research Laboratories, Froedtert and Medical College of Wisconsin, WI, USA), Humaid Al-Shamsi (Director of Oncology Services, Burjeel Holdings; Professor, Gulf Medical University; President, Emirates Oncology
Society, Abu Dhabi, UAE), and Khaled Musallam (Group Chief Research Officer, Burjeel Holdings; Adj. Professor, Khalifa University, Abu Dhabi, UAE).

View the full article here: Download pdf